Delisting (new) — Company received formal Nasdaq notice of non-compliance with minimum bid price requirement and faces potential delisting by September 2026.
Going Concern (new) — Auditor expressed substantial doubt about the company's ability to continue as a going concern in the 2025 audit report due to recurring losses and limited cash runway.

NASDAQ: SKYE Skye Bioscience, Inc. 10-Q

Skye Bioscience faces Nasdaq delisting risk; Phase 2a monotherapy missed endpoint

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SKYE commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 1, 2026 6:46 PM